ENDRA CFO granted 13,461 restricted shares

ENDRA Life Sciences Inc. reported that its Chief Financial Officer, Richard Jacroux, received a grant of 13,461 shares of common stock as a stock award.

Rhea-AI Filing Summary

ENDRA Life Sciences Inc. reported that its Chief Financial Officer, Richard Jacroux, received a grant of 13,461 shares of common stock as a stock award. The shares, structured as restricted stock units that convert one-for-one into common stock, will vest in full on June 11, 2026. Following this award, Jacroux holds 33,461 shares of common stock, including unvested restricted stock units.

Insider Trade Summary

Grant/Award: 13,461 shares

Grant/Award 1 txn

Insider Jacroux Richard

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	13,461	$0.00	$0.00

Holdings After Transaction: Common Stock — 33,461 shares (Direct)

Footnotes (2)

1. F1. Holdings include unvested restricted stock units ("RSUs").
2. F2. Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NDRA disclose for Richard Jacroux?

ENDRA Life Sciences disclosed that Chief Financial Officer Richard Jacroux acquired 13,461 shares of common stock via a stock award. The award is in the form of restricted stock units that will convert into common shares once they fully vest on June 11, 2026.

How many NDRA shares did the CFO receive in the latest Form 4 filing?

The Chief Financial Officer received 13,461 shares of ENDRA Life Sciences common stock through a grant classified as a stock award. These shares are currently unvested restricted stock units that will convert into common stock on a one-for-one basis when they vest on June 11, 2026.

At what price were the NDRA shares granted to the CFO?

The 13,461 ENDRA Life Sciences shares granted to the Chief Financial Officer were reported at a price of $0.0000 per share. This indicates the award was part of equity compensation, rather than an open-market purchase, and reflects a non-cash grant of restricted stock units to the executive.

When will the NDRA restricted stock units granted to the CFO vest?

The restricted stock units granted to ENDRA Life Sciences’ Chief Financial Officer will vest in full on June 11, 2026. At that time, the RSUs will convert into common stock on a one-for-one basis, turning the entire grant into freely issued common shares for the executive.

How many NDRA shares does the CFO hold after this Form 4 transaction?

After the reported stock award, ENDRA Life Sciences’ Chief Financial Officer holds a total of 33,461 shares of common stock. This figure includes unvested restricted stock units, which will convert into common shares when they vest, providing the executive with a larger overall equity position.

What type of equity compensation did NDRA grant to its CFO?

ENDRA Life Sciences granted its Chief Financial Officer restricted stock units as equity compensation, representing 13,461 shares of common stock. These RSUs convert to common stock on a one-for-one basis and will vest in full on June 11, 2026, aligning the executive’s incentives with shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 09:48 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jacroux Richard

(Last) (First) (Middle)

3600 GREEN COURT

SUITE 350

(Street)

ANN ARBOR MI 48105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ENDRA Life Sciences Inc. [ NDRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/02/2026		A		13,461(2)	A	$0	33,461(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Holdings include unvested restricted stock units ("RSUs").

2. Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026.

	/s/ Richard Jacroux by Coleman Wombwell, attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.